available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(f)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 26, 2016.

A. Federal Reserve Bank of Minneapolis (Jacquelyn K. Brunmeier, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55408–0291:

Michele T. Fennell, Assistant Secretary of the Board.

[FR Doc. 2016–18242 Filed 8–1–16; 8:45 am]
BILLING CODE 6210–01–P

GENERAL SERVICES ADMINISTRATION

[Notice–CSE–2016–04; Docket No. 2016–0002; Sequence No. 18]

Notice of the General Services Administration’s Labor-Management Relations Council Meeting

AGENCY: Office of Human Resources Management (OHRM), General Services Administration (GSA).

ACTION: Notice of meeting.

SUMMARY: The General Services Administration’s Labor-Management Relations Council (GLMRC), a Federal Advisory Committee established in accordance with the Federal Advisory Committee Act (FACA), 5 U.S.C., App., and Executive Order 13522, plans to conduct throughout the United States. Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 26, 2016.

Michele T. Fennell, Assistant Secretary of the Board.

[FR Doc. 2016–18242 Filed 8–1–16; 8:45 am]
BILLING CODE 6210–01–P

GENERAL SERVICES ADMINISTRATION


Federal Travel Regulation (FTR); Reimbursement for Use of Transportation Network Companies While on Official Travel

AGENCY: Office of Government-wide Policy (OGP), General Services Administration (GSA).

ACTION: Notice of a bulletin.

SUMMARY: The purpose of this notice is to inform agencies that FTR Bulletin 16–05, pertaining to the authorization of and reimbursement for use of Transportation Network Companies (TNCs) by Federal travelers on temporary duty, is now available online at www.gsa.gov/ftrbulletin.

DATES: Effective: August 2, 2016.

FOR FURTHER INFORMATION CONTACT: Ms. Jill Denning, Program Analyst, Office of Asset and Transportation Management (MAT), OGP, GSA, at 202–208–7642 or via email at jill.denning@gsa.gov. Please cite FTR Bulletin 16–05.
S U M M A R Y: The Food and Drug Administration (FDA) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.

D A T E S: Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests on an FDA advisory committee or panel may send a letter or email stating that interest to FDA (see ADDRESSES) by September 1, 2016, for vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see ADDRESSES) by September 1, 2016. Nominations will be accepted for current vacancies and for those that will or may occur through January 31, 2017.

A D D R E S S E S: All statements of interest from consumer organizations interested in participating in the selection process and consumer representative nominations should be submitted electronically to Kimberly.Hamilton@fda.hhs.gov. For questions relating to specific advisory committees or panels, contact the appropriate Contact Person listed in table 1 in the SUPPLEMENTARY INFORMATION section.

S U P P L E M E N T A R Y I N F O R M A T I O N: For further information contact: For questions relating to participation in the selection process: Kimberly Hamilton, Advisory Committee Oversight and Management Staff (ACOMS), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993–0002, or by FAX at: 301–847–8640. Additional information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA’s Web site at: http://www.fda.gov/AdvisoryCommittees/default.htm.

A D D R E S S E S: For questions relating to specific advisory committees or panels, contact the appropriate Contact Person listed in table 1 in the SUPPLEMENTARY INFORMATION section.

S U P P L E M E N T A R Y I N F O R M A T I O N: For further information contact: For questions relating to participation in the selection process: Kimberly Hamilton, Advisory Committee Oversight and Management Staff (ACOMS), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993–0002, or by FAX at: 301–847–8640. Additional information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA’s Web site at: http://www.fda.gov/AdvisoryCommittees/default.htm.

F O R F U R T H E R I N F O R M A T I O N C O N T A C T: For questions relating to specific advisory committees or panels, contact the appropriate Contact Person listed in table 1 in the SUPPLEMENTARY INFORMATION section.

S U P P L E M E N T A R Y I N F O R M A T I O N: For further information contact: For questions relating to specific advisory committees or panels, contact the appropriate Contact Person listed in table 1 in the SUPPLEMENTARY INFORMATION section.

T A B L E 1—A D V I S O R Y C O M M I T T E E C O N T A C T S

<table>
<thead>
<tr>
<th>Contact person</th>
<th>Committee/panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cindy Hong, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2430, Silver Spring, MD 20993–0002, phone: 301–796–0889, email: <a href="mailto:Cindy.Hong@fda.hhs.gov">Cindy.Hong@fda.hhs.gov</a>.</td>
<td>Gastrointestinal Drugs Advisory Committee.</td>
</tr>
<tr>
<td>Jennifer Shepherd, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2434, Silver Spring, MD 20993–0002, phone: 301–796–4043, email: <a href="mailto:Jennifer.Shepherd@fda.hhs.gov">Jennifer.Shepherd@fda.hhs.gov</a>.</td>
<td>Medical Imaging Advisory Committee.</td>
</tr>
</tbody>
</table>